A carregar...
Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report
Abstract Background Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingual (SL) buprenorphine/naloxone is taken as prescribed; it is thought to...
Na minha lista:
| Publicado no: | Harm Reduction Journal |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Publicado em: |
BMC
2024-07-01
|
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12954-024-01054-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|